- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01930110
Closed-loop Control of Glucose Levels (Artificial Pancreas) During Exercise in Adults With Type 1 Diabetes
An Open-label, Randomized, Cross-over Study to Compare the Efficacy of Single-hormone Closed-loop Strategy and Dual-hormone Closed-loop Strategy at Regulating Glucose Levels During Continuous Exercise and Interval Exercise in Adults With Type-1 Diabetes
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings. A dual-hormone closed-loop system would regulate glucose levels through the infusion of two hormones: insulin and glucagon.
The objective is to compare the efficacy of single-hormone closed-loop strategy and dual-hormone closed-loop strategy at regulating glucose levels during continuous exercise and interval exercise.
The investigator hypothesized that dual-hormone closed-loop strategy is superior to single-hormone closed-loop strategy in regulating glucose levels during exercise periods.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings. A dual-hormone closed-loop system would regulate glucose levels through the infusion of two hormones: insulin and glucagon.
We aim to conduct a randomized two-way cross-over trial comparing single-hormone closed-loop strategy and dual-hormone closed-loop strategy to compare the two interventions during exercise periods in adults with type 1 diabetes. A moderate intensity exercise will be performed for 60 minutes at 60% of the maximum oxygen consumption (VO2max). A high intensity exercise will be 40 minutes of interval training. The interval training will be preceded by a 10 minutes warm-up and followed by a 10 minutes cool down.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Quebec
-
Montreal, Quebec, Canada, H2W 1R7
- Institut de Recherches Cliniques de Montréal
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Males and females ≥ 18 years of old.
- Clinical diagnosis of type 1 diabetes for at least one year.
- The subject will have been on insulin pump therapy for at least 3 months.
- Last (less than 3 months) HbA1c ≤ 12%.
Exclusion Criteria:
- Clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy as judged by the investigator.
- Recent (< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.
- Ongoing pregnancy.
- Severe hypoglycemic episode within two weeks of screening.
- Other serious medical illness likely to interfere with study participation or with the ability to complete the exercise periods by the judgment of the investigator (e.g. orthopedic limitation).
- Failure to comply with team's recommendations (e.g. not willing to eat snack, not willing to change pump parameters, etc).
- Problems with venous access
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: Single-hormone closed-loop system
In single-hormone closed-loop system, variable subcutaneous insulin infusion rate will be used to regulate glucose levels
|
Patients will be admitted at the research clinical facility at 14:30.
Closed-loop strategy will start at 15:30.
At 18:00, patients will performed a 60-minute exercise at 60% of VO2 max.
Patients will be discharged at 20:00.
Patients will be admitted at the research clinical facility at 14:30.
Closed-loop strategy will start at 15:30.
At 18:00, patients will performed a 40-minute interval exercise.
Patients will be discharged at 20:00.
|
Actieve vergelijker: Dual-hormone closed-loop system
In dual-hormone closed-loop system, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels
|
Patients will be admitted at the research clinical facility at 14:30.
Closed-loop strategy will start at 15:30.
At 18:00, patients will performed a 60-minute exercise at 60% of VO2 max.
Patients will be discharged at 20:00.
Patients will be admitted at the research clinical facility at 14:30.
Closed-loop strategy will start at 15:30.
At 18:00, patients will performed a 40-minute interval exercise.
Patients will be discharged at 20:00.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
The number of patients experiencing exercise-induced hypoglycemia requiring dextrose infusion (< 3.3 mmol/L symptomatic or < 3.0 mmol/L regardless of symptoms).
Tijdsspanne: 18:00 hours to 19:30 hours
|
18:00 hours to 19:30 hours
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Decrease in glucose levels during each exercise
Tijdsspanne: 18:00 to 19:30 hours or 18:00 to 19:10 depending on the exercise performed
|
Difference between glucose levels at the beginning of the exercise and the lowest glucose level from the start of the exercise until 30 minutes after exercise).
|
18:00 to 19:30 hours or 18:00 to 19:10 depending on the exercise performed
|
Area under the curve of plasma glucose levels < 4 mmol/L
Tijdsspanne: 15:30 hours to 19:30 hours
|
15:30 hours to 19:30 hours
|
|
Percentage of time of plasma glucose levels < 4 mmol/L
Tijdsspanne: 15:30 hours to 19:30 hours
|
15:30 hours to 19:30 hours
|
|
Number of patients with an exercise-induced hypoglycemia < 3.9 mmol/L
Tijdsspanne: 15:30 hours to 19:30 hours
|
15:30 hours to 19:30 hours
|
|
Decremental area under the curve from the start of the exercise for 90 minutes.
Tijdsspanne: 18:00 to 19:30
|
18:00 to 19:30
|
|
Percentage of time-in-target defined as between 4 and 10 mmol/L
Tijdsspanne: 15:30 hours to 19:30 hours
|
15:30 hours to 19:30 hours
|
|
Mean time (minutes) to the first hypoglycemic event during the exercise period
Tijdsspanne: 18:00 to 19:00
|
18:00 to 19:00
|
|
The amount of dextrose infused
Tijdsspanne: 15:30 to 19:30
|
15:30 to 19:30
|
Medewerkers en onderzoekers
Medewerkers
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CLASS-06
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Diabetes type 1
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.VoltooidDiabetes mellitus, type 1 | Diabetes type 1 | Diabetestype1 | Diabetes mellitus type 1 | Auto-immuun diabetes | Diabetes Mellitus, insulineafhankelijk | Jeugddiabetes | Diabetes, auto-immuunziekte | Insulineafhankelijke diabetes mellitus 1 | Diabetes Mellitus, insulineafhankelijk, 1 | Diabetes Mellitus,... en andere voorwaardenVerenigde Staten
-
Capillary Biomedical, Inc.VoltooidDiabetes mellitus, type 1 | Diabetes type 1 | Diabetes mellitus type 1 | Diabetes Mellitus, insulineafhankelijk, 1Australië
-
University of California, San FranciscoJuvenile Diabetes Research FoundationVoltooidDiabetes mellitus type 1 | Diabetes mellitus, type I | Insulineafhankelijke diabetes mellitus 1 | Diabetes Mellitus, insulineafhankelijk, 1 | IDDMVerenigde Staten, Australië
-
Poznan University of Medical SciencesOnbekendDiabetes mellitus type 1 | Remissie van diabetes type 1 | Chronische complicaties van diabetesPolen
-
Capillary Biomedical, Inc.BeëindigdDiabetes type 1 | Diabetes mellitus type 1 | Diabetes mellitus, type I | Diabetes Mellitus, insulineafhankelijk, 1 | IDDMOostenrijk
-
Eledon PharmaceuticalsIngetrokkenBroze type 1 diabetes mellitusVerenigde Staten
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)VoltooidDiabetes mellitus type 1 | T1DM | T1D | Nieuwe diabetes mellitus type 1Verenigde Staten, Australië
-
Shanghai Changzheng HospitalWervingBroze type 1 diabetes mellitusChina
-
University Hospital Inselspital, BerneVoltooidDiabetes complicaties | Diabetes mellitus type 1Zwitserland
-
Spiden AGDCB Research AGWervingDiabetes mellitus type 1 | Diabetes mellitus type 1 met hypoglykemie | Diabetes mellitus type 1 met hyperglykemieZwitserland
Klinische onderzoeken op 60-minute exercise
-
Region Örebro CountyWervingMechanische ventilatie | Atelectase | Verdeling van ventilatieZweden
-
Winthrop University HospitalBeëindigd
-
Grünenthal GmbHVoltooidPijn | Chronische pijn | Neuropatische pijn | Viscerale pijnDuitsland
-
St. Luke's Rehabilitation InstituteWashington State UniversityWervingHartinfarct | Traumatische hersenschade | Niet-traumatisch hersenletselVerenigde Staten
-
Barry LondonBeëindigdHartfalen | RechterbundeltakblokVerenigde Staten
-
University of BathBiotechnology and Biological Sciences Research CouncilVoltooidVitamine D | Acute oefeningVerenigd Koninkrijk
-
Chong Kun Dang PharmaceuticalSeoul National University HospitalVoltooidBloedarmoedeKorea, republiek van
-
Chong Kun Dang PharmaceuticalSeoul National University HospitalVoltooidBloedarmoedeKorea, republiek van
-
Vanderbilt UniversityVoltooidZiekte van ParkinsonVerenigde Staten
-
Sobi, Inc.BeëindigdTrombocytopenieVerenigde Staten